Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,029 across all filing types
Latest filing 2021-01-12 Major Shareholding Noti…
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G
Major Shareholding Notification
2021-01-12 English
SC 13G
Major Shareholding Notification
2021-01-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a securities purchase agreement, issuance of shares and warrants, registration rights, and related agreements. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or earnings release. The document is a regulatory filing announcing a material definitive agreement and related equity financing transactions. It fits the category of Regulatory Filings (RNS) as it does not fall into more specific categories and is a general SEC current report filing.
2021-01-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, an amendment to a Current Report filed with the SEC. It provides financial statements and pro forma financial information related to a business acquisition (Jay Pharma, Inc.). The document includes audited and unaudited financial statements and pro forma combined financials, but it is an amendment to a current report rather than a full annual or quarterly report. The content focuses on financial disclosures related to a specific event (acquisition) rather than a comprehensive annual or quarterly report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories like 10-K or IR. The document is not a full Annual Report (10-K), Interim Report (IR), or Audit Report (AR) standalone, but an amendment to a current report providing financial statements related to an acquisition event.
2021-01-11 English
Director's Dealing 2021
Director's Dealing
2021-01-08 English
Director's Dealing 2021
Director's Dealing
2021-01-08 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.